Center for Immunotherapy, Vaccines and Virotherapy, The Biodesign Institute, Arizona State University, Tempe, AZ, USA.
Department of Molecular Genetics and Microbiology, University of Florida, Gainesville, FL, USA.
Methods Mol Biol. 2021;2225:63-75. doi: 10.1007/978-1-0716-1012-1_4.
Myxoma virus (MYXV) has proven to be an effective candidate for oncolytic virotherapy in many preclinical cancer models. As a nonhuman pathogen, MYXV does not need to overcome any preexisting antiviral immunity, and its DNA cannot integrate into the host genome, making it an extremely safe vector. Moreover, the large dsDNA genome of MYXV allows the insertion of multiple transgenes and the design of engineered recombinant oncolytic viruses (OVs) with enhanced immunostimulatory or other desired properties. In this chapter, we describe detailed protocols for the generation and characterization of transgene-armed recombinant MYXV vectors.
粘液瘤病毒（MYXV）已被证明是许多临床前癌症模型中溶瘤病毒治疗的有效候选者。作为一种非人类病原体，MYXV 不需要克服任何预先存在的抗病毒免疫，并且其 DNA 不能整合到宿主基因组中，使其成为一种极其安全的载体。此外，MYXV 的大型 dsDNA 基因组允许插入多个转基因，并设计具有增强的免疫刺激性或其他所需特性的工程重组溶瘤病毒（OV）。在本章中，我们描述了携带转基因的重组 MYXV 载体的生成和表征的详细方案。
